Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionano Genomics, Inc.BNGO · Entity 7831 | Director | June 06, 2019 | June 10, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionano Genomics, Inc.
Report date June 06, 2019 · Filed June 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.78 · Expires 2029-06-06 | Direct | 21,911 |
Reported balance
After 2019-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-06 · Grant · Acquired 21,911 · Balance 21,911 F1: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 6, 2020, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 6, 2020, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2019 Filed Jun 10, 2019 21:34 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 21,911 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001209191-19-035900 · doc4.xml · derivative · entry 1 Cai Darren · CIK 0001746824 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,911 Underlying: Common Stock · 21,911 shares Expires 2029-06-06 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 6, 2020, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:25 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 10,516 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001209191-18-053805 · doc4.xml · derivative · entry 1 Cai Darren · CIK 0001746824 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,516 Underlying: Common Stock · 10,516 shares Expires 2028-09-30 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 36 months beginning on the one-month anniversary of October 1, 2018 (the "Vesting Commencement Date") such that the option shall be fully vested and exercisable on the three year anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.